Rationale: Continuously refining and advancing the strategies and methods employed in sports drug testing is critical for efficient doping controls. Besides improving and expanding the spectrum of target analytes, alternative test matrices have warranted in-depth evaluation as they commonly allow for minimal-/non-invasive and non-intrusive sample collection. In this study, the potential of exhaled breath (EB) as doping control specimen was assessed.
the metabolic modulator meldonium, and the beta-blocker bisoprolol was detected in exhaled breath.
Conclusions:
The EB aerosol has provided a promising proof-of-concept suggesting the expansion of this testing strategy as a complement to currently utilized sports drug testing programs.
| INTRODUCTION
Routine sports drug testing has become a challenging mission in the face of the ever-growing exigencies resulting from the breadth of relevant target analytes, drug detection windows, financial implications, etc., 1, 2 but also from the desire to reduce the intrusiveness and invasiveness of the sample collection procedure for the athlete. 3 Consequently, assessing the utility of test matrices representing alternatives to commonly sampled blood and urine specimens such as dried blood spots (DBS), [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] hair, [17] [18] [19] and oral fluid (OF) [20] [21] [22] has been the subject of a number of studies related to doping controls. In addition, exhaled breath (EB) has received increasing attention as a potential test matrix particularly for clinical and forensic drug testing applications. [23] [24] [25] [26] [27] [28] [29] [30] [31] Initially, EB was considered exclusively for the analysis of volatile compounds; however, a considerable in and being eliminated into EB, 32 nourishing the concept of EB as a viable complement to routine doping controls. Based on the identification of these non-volatile analytes (predominantly contained in the alveolar lining fluid and surfactant) in EB, 33, 34 the formation of the breath aerosol was suggested to include bronchiolar and alveolar components. 35, 36 Lung surfactant and surface lining fluid are separated from the blood stream by several barriers including the alveolar epithelium, the basement membranes of the alveolar epithelium and the capillary endothelium, and the capillary endothelium; nevertheless, plasma proteins are found in lavage fluid (transported by yet not fully clarified mechanisms exhibiting an inverse relationship between alveolar permeability and molecular mass), and pulmonary drug delivery has become routine for numerous therapeutics. 37, 38 In consideration of these aspects and the proven traceability of drugs of abuse and selected therapeutics in EB, 23, [26] [27] [28] 30, 39, 40 
| Liquid chromatography/tandem mass spectrometry (LC/MS/MS)
All analyses were conducted using a Aquity I-Class ultra-performance liquid chromatography (UPLC) system (Waters, Eschborn, Germany) interfaced via unispray (US) ionization to a Xevo TQ-XS tandem mass spectrometer (Waters). The LC system was equipped with a Poroshell C-8 analytical column (50 × 3.0 mm, 2.7 μm particle size; Agilent, Waldbronn, Germany). The LC method employed 10 mM aqueous ammonium acetate (solvent A) and acetonitrile (solvent B) and gradient elution starting with 95% A, decreasing to 0% A in 10 min, maintaining 0% A for 2 min before re-equilibration at 95% A for 2.5 min. The US source was operated in positive mode using an impactor voltage of 1 kV and the mass spectrometer recorded two diagnostic precursor/ product ion pairs per analyte in multiple reaction monitoring (MRM)
mode. The collision gas was nitrogen (provided by a nitrogen generator, CMC, Eschborn, Germany), and collision energies were optimized for each ion transition as summarized in Table 1 .
| Stock and working solutions
Stock solutions of all model compounds were prepared at 1 mg/mL in methanol and stored at -20°C. Working solutions (10 μg/mL and 0.1 μg/mL) were prepared by dilution of the stock solution on the day of use and discarded after 24 h. A mixture of internal standards (ISTDs) containing (S)-2-aminooctane, D 3 -meldonium, D 3 -testosterone, and D 7 -propranolol was prepared in methanol at a concentration of 10 μg/mL, which was diluted to a working solution of 0.1 μg/mL for daily batch processing purposes.
| Sample preparation
The SensAbues EB collection devices were extracted by adding a total of 4 mL of methanol (plus 1 ng each of aminooctane, D 3 -meldonium, 
| Method characterization
The characteristics of the test method, including limits of detection (LODs), analyte recovery, assay imprecision, and specificity, were determined by different experiments. Specificity was assessed by Only one precursor/product ion pair found at a S/N > 3. *one precursor/product ion pair per analyte **two precursor/product ion pairs per analyte meeting World Anti-Doping Agency (WADA) criteria for the identification of non-threshold substances analyzing 20 blank samples from different individuals (10 male and 10 female volunteers) and probing for interfering signals at diagnostic precursor/product ion pairs at expected analyte retention times. LODs were deduced from the same set of blank specimens calculating the average noise for each target analyte at the expected retention time using one diagnostic precursor/product ion pair. The signal obtained from spiked EB samples (prepared at 10, 100, 500, and 1000 pg/filter) had to exceed the average noise plus a threefold standard deviation by at least a factor of 3 (signal-to-noise ratio (S/N) >3). Accordingly, the identification capability was computed, necessitating two diagnostic precursor/product ion pairs meeting 100 pg/filter, medium: 500 pg/filter, high: 1000 pg/filter).
| RESULTS AND DISCUSSION
Collecting analytes from EB has been accomplished by various different strategies in the past including cooling traps (yielding exhaled breath condensate, EBC), 32, 36 breathing through tubing with silica-coated glass fiber discs, 23 and capturing aerosol particles by means of electrostatic filtration media. [28] [29] [30] In consideration of the modus operandi of electrostatic filtration media, i.e. the interaction and retention of charged aerosol particles on the electret fiber material supported by Coulombic and dielectrophoretic forces, and the breadth of target analytes relevant for doping controls, commercially available standardized EB collection devices equipped with electrostatic filter units were employed in the present study. This pilot study aimed at assessing whether EB sampling can contribute to modern sports drug testing programs and included the development of a test method focusing on four classes of substances prohibited in sports, 41 i.e.
anabolic agents (substance class S1), hormone and metabolic modulators (S4), stimulants (S6), and beta-blockers (P2), and the analysis of proof-of-concept samples indicating the practicality or impracticality of EB as alternative matrix in doping controls.
| Method characterization
Method development and subsequent characterization was conducted by means of breath-ventilated filter media of EB collection devices, which were spiked with 12 model substances ( Table 1) at levels commonly targeted and found in EB analysis. 29, 31 For all analytes, two diagnostic precursor/product ion pairs were selected and corresponding collision energies were optimized for maximum signal abundance ( Table 1 ). The ion transitions conventionally consisted of the protonated molecules and respective characteristic product ions in all cases except for the steroidal selective androgen receptor modulator (SARM) drug candidate YK-11 (analyte 2, Table 1 
was selected as the precursor ion owing to the fragile nature of the protonated molecule. 42, 43 All chosen ion transitions proved specific as no interfering signals were observed in extracted ion chromatograms of 20 blank EB samples, one of which is illustrated in Figure 1A . In contrast, specimens spiked with 500 pg of each model substance resulted in unequivocal signals using the established LC/ MS/MS method ( Figure 1B) . As comprehensiveness of the analytical approach is particularly desirable, only one sample preparation protocol was chosen and parameters potentially influencing analyte recovery were not optimized for the different classes of compounds. However, the observed recoveries (54-104%) and corresponding LODs of the tested analytes (5-100 pg/filter) as well as assay imprecision data (3-20%) were found appropriate for the intended purpose of allowing for an initial testing procedure indicating the presence or absence of a doping agent in EB as summarized in Table 1 .
3.2 | Elimination study samples -proof-of-concept 
| CONCLUSIONS
The results of this pilot study and literature data from the field of therapeutic drug monitoring and forensic analyses [23] [24] [25] [26] [27] [28] [29] [30] [31] 40 indicate that drugs of rather different physico-chemical nature are traceable in EB.
Consequently, a considerable number of compounds relevant for doping controls could be monitored via EB sampling in potential future sports drug testing programs that could utilize the non-invasive sample collection approach of exhaled breath. To date, information on analyte concentrations in EB, detection times, etc., are still limited to a small number of relevant compounds. Hence, follow-up studies are required to assess the full potential of EB as an alternative matrix in doping controls, and a considerable expansion of the spectrum of compounds that can be monitored from EB is needed. This necessitates utmost analytical sensitivity considering the minute amounts of target analytes expected to be eliminated via an athletes' breath.
